Clinical Trials Logo

Hutchinson-Gilford Syndrome clinical trials

View clinical trials related to Hutchinson-Gilford Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT00879034 Completed - Progeria Clinical Trials

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Start date: March 2009
Phase: Phase 2
Study type: Interventional

This is an open label single arm feasibility trial. A combination of two oral agents (pravastatin and lonafarnib) and one intravenous (IV) agent (zoledronic acid) will be administered at doses and schedule currently applied in pediatrics. These agents all target farnesylation pathways at different points. Our goal is to inhibit farnesylation of abnormal lamin, the disease-causing protein in Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies (henceforth "progeria"). The drugs will include the intravenous bisphosphonate zoledronic acid, oral HMG co-reductase inhibitor pravastatin and the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH 66336). Patients with genetically confirmed progeria will be eligible for this protocol. Treatment will be initiated for 4 weeks duration and may be extended depending on tolerability. This study will assess the feasibility of this treatment regimen in the first 4 weeks. If tolerated for 4 weeks, patients can be treated with this regimen for up to 6 months.

NCT ID: NCT00425607 Completed - Progeria Clinical Trials

Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.